Search Results 241-250 of 17405 for Interferon

1. https://www.mayoclinic.org/chinese_patient_consumer_faq.xml

2. Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer - Mayo Clinic

   interferon and interleukin 2 [IL-2]) =< 4 weeks or 5 drug elimination half-lives (whichever is longer) prior to randomization - Prior treatment with CD137 ...

3. https://www.mayoclinic.org/spanish_patient_consumer_faq.xml

4. OCEAN (depemOkimab effiCacy Eosinophilic grAnulomatosis with polyaNgiitis) - Mayo Clinic

   ... Interferon-alpha within 6 months prior to Screening Visit 1, Anti-tumor necrosis factor therapy within 12 weeks prior to Screening Visit 1, Anti-CD52 ...

5. Mayo Clinic's approach to Peyronie's disease: Nonsurgical interventions

   "Finally, intralesional injections directly into the penile plaque with medications such as verapamil, interferon alpha-2β and collagenase clostridium ...

6. Publications - Amir A. Sadighi Akha, M.D., Ph.D. - Mayo Clinic

   Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway.

7. Antihemophilic factor (recombinant) porcine sequence (intravenous route) - Side effects & dosage - Mayo Clinic

   Antihemophilic factor (AHF) recombinant porcine sequence injection is used to treat serious bleeding episodes in patients with acquired hemophilia A. The ...

8. A Study to Evaluate M7824 with Concurrent Chemoradiation (cCRT) in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) - Mayo Clinic

   ... interferon are not allowed) at study entry and with planned monitoring and management according to appropriate labeling guidance. Participants on active HCV ...

9. A Study to Evaluate the Effectiveness, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera - Mayo Clinic

   Patients previously treated with MDM2 antagonist therapies or patients receiving interferon-alpha, anagrelide, or ruxolitinib within 28 days or 5 half-lives ...

10. A Study to Evaluate Gemcitabine and MK-3475 (Pembrolizumab) to Treat Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mayo Clinic

    Patients must not have received any prior or concurrent systemic chemotherapy or immunotherapy (prior intravesical chemotherapy and interferon is permitted).